Yuhan Corporation announced on the 4th that it has signed a comprehensive research and development collaboration agreement with Progen, which is developing next-generation obesity and diabetes treatments based on the bispecific antibody platform NTIG technology. Through this collaboration, Yuhan plans to strengthen its partnership with Progen and unite efforts to develop next-generation biopharmaceuticals and enhance global market competitiveness through a new drug development committee composed of experts from both companies.
Progen's NTIG platform is evaluated to enable the development of multi-target fusion proteins, bispecific antibodies, and antibody-drug conjugates (ADC) with increased protein stability and extended half-life in the bloodstream, and it has excellent scalability for various diseases. Through this agreement, the two companies have selected an immuno-oncology bispecific antibody as their first joint development project and plan to select subsequent joint development projects as well.
Jo Wook-je, CEO of Yuhan Corporation, said, "Through this comprehensive research and development (R&D) collaboration agreement with Progen, we will continue ongoing technology exchange and cooperation with Progen," adding, "We hope this will be an opportunity to secure an innovative drug pipeline with global competitiveness." Kim Jong-gyun, CEO of Progen, also stated, "Through this agreement, we will not only share trust and future vision between the two companies but also synergize our strengths in advanced drug development to further enhance the company's growth and competitiveness in the global market."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
